{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:14:24Z","timestamp":1791342864740,"version":"4.3.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/jac\/dkx354","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T11:09:07Z","timestamp":1505128147000},"page":"134-142","source":"Crossref","is-referenced-by-count":39,"title":["Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-0778","authenticated-orcid":false,"given":"Jochem B","family":"Buil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J M","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland E","family":"Wasmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques F","family":"Meis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem J G","family":"Melchers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-9860","authenticated-orcid":false,"given":"Paul E","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,18]]},"reference":[{"key":"key\n\t\t\t\t20171215014104_dkx354-B1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.200505-727SO","article-title":"Current approaches to diagnosis and treatment of invasive aspergillosis","volume":"173","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B3","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current concepts in antifungal pharmacology","volume":"86","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: a new extended spectrum triazole for invasive mold diseases","volume":"10","year":"2015","journal-title":"Future Microbiol"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B6","doi-asserted-by":"crossref","first-page":"7882","DOI":"10.1128\/AAC.02107-15","article-title":"Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphotericin B against molecularly identified Mucorales species","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21-22","year":"2015","journal-title":"Drug Resist Updat"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B9","author":"EUCAST","year":"2015"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B10","doi-asserted-by":"crossref","first-page":"571.e1","DOI":"10.1016\/j.cmi.2016.01.017","article-title":"EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents","volume":"22","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B11","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B12","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.04907-14","article-title":"Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B13","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1128\/AAC.02665-15","article-title":"Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B14","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1128\/AAC.01355-13","article-title":"Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B15","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B16","article-title":"Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2014. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2014.01.001","article-title":"Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp","volume":"16","year":"2013","journal-title":"Drug Resist Updat"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.05088-11","article-title":"Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B19","doi-asserted-by":"crossref","first-page":"e50.","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and Simulation Workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B20","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jac\/dku477","article-title":"A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients","volume":"70","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B21","doi-asserted-by":"crossref","first-page":"e50034","DOI":"10.1371\/journal.pone.0050034","article-title":"Discovery of a hapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B22","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jac\/dkt075","article-title":"The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus","volume":"68","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B23","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1128\/AAC.01599-09","article-title":"Azole resistance profile of amino acid changes in Aspergillus fumigatus cyp51A based on protein homology modeling","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B24","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1128\/AAC.03779-14","article-title":"EUCAST testing of isavuconazole susceptibility in Aspergillus: comparison of results for inoculum standardization using conidium counting versus optical density","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B25","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1128\/AAC.01111-13","article-title":"Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B26","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/AAC.01530-08","article-title":"In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"53","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dku364","article-title":"Azole, polyene and echinocandin MIC distributions for wild-type, TR34\/L98H and TR46\/Y121F\/T289A Aspergillus fumigatus isolates in the Netherlands","volume":"70","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?","volume":"9","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B29","article-title":"Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B30","doi-asserted-by":"crossref","first-page":"e1003633","DOI":"10.1371\/journal.ppat.1003633","article-title":"Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health","volume":"9","year":"2013","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B32","article-title":"Clinical implications of globally emerging azole resistance in Aspergillus fumigatus","volume":"371","year":"2016","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1586\/14787210.2013.826989","article-title":"Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis","volume":"11","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B34","author":"FDA Advisory Committee Briefing Document","year":"2015"},{"key":"key\n\t\t\t\t20171215014104_dkx354-B35","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/1\/134\/22755695\/dkx354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T16:30:52Z","timestamp":1659457852000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/73\/1\/134\/4557573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,10,18]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx354","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2017,10,18]]}}}